169 results on '"Nahass, Ronald G."'
Search Results
2. WED-371 Imdusiran (AB-729) administered every 8 weeks in combination with 24 weeks of pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection leads to HBsAg loss in some subjects at end of IFN treatment
3. Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection
4. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
5. Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection
6. Development of a dual channel detection system for pan-genotypic simultaneous quantification of hepatitis B and delta viruses.
7. The Association of Serotonin Toxicity with Combination Linezolid–Serotonergic Agent Therapy: A Systematic Review and Meta-Analysis
8. The risk of cardiac events in patients who received concomitant levofloxacin and amiodarone
9. Impact of tocilizumab administration on mortality in severe COVID-19
10. Preliminary safety and antiviral activity of AB-729 combination treatment with pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection
11. Multisystem Inflammatory Syndrome in an Adult After COVID-19
12. Relationship between Body Composition and Serum Immunoglobulin Concentrations after Administration of Intravenous Immune Globulin–Preclinical and Clinical Evidence
13. Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection
14. Cefoxitin Plasma and Subcutaneous Adipose Tissue Concentration in Patients Undergoing Sleeve Gastrectomy
15. Hypertrophic Herpes Simplex—Pseudocarcinoma
16. The Infectious Diseases Physician in the Future of Healthcare: Not Only About Antibiotic Prescribing
17. Deeper virologic suppression with the addition of vebicorvir, a first-generation hepatitis B core inhibitor, to entecavir correlates with reduced inflammation and fibrosis-4 index in treatment naïve patients with HBeAg positive chronic hepatitis B
18. Comparative Efficacy of Early COVID-19 Monoclonal Antibody Therapies: A Retrospective Analysis
19. Successful Treatment of Cutibacterium acnes Prosthetic Joint Infection With Single-Stage Exchange and Oral Antibiotics.
20. The Value of Infectious Diseases Specialists: Non-Patient Care Activities
21. 909. Treating Hepatitis C Virus (HCV) in Young Adult Active Drug Users Is Possible
22. 512. Does Time From COVID-19 Symptom Onset to Administration of Anti-spike Protein Monoclonal Antibody Predict Response?
23. 615. A Year with COVID19 – Experience from the Front Line in a Large Infectious Disease (ID) Clinical Practice
24. 814. Successful Treatment of Cutibacterium acnes (CA) Prosthetic Device Infection (PDI) with Oral Linezolid and Rifampin (LR)
25. Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial
26. The infectious disease service line: next frontier in hospital/physician co-management?
27. Linkage to care for suburban heroin users with hepatitis C virus infection, New Jersey, USA
28. Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failed
29. "Unwinding Our COVID 19 Pandemic Safeguards After Vaccination"
30. Comparative Efficacy of Early COVID-19 Monoclonal Antibody Therapies: A Retrospective Analysis.
31. Remdesivir for 5 or 10 Days in Patients With Severe Covid-19
32. LBP-38 - Preliminary safety and antiviral activity of AB-729 combination treatment with pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection
33. Impact of Hydroxychloroquine on Mortality in Hospitalized Patients with COVID-19: Systematic Review and Meta-Analysis
34. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
35. Electronic Health Record Technology
36. Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19
37. Impact of tocilizumab administration on mortality in severe COVID-19
38. Acid Suppression Medications During Hospitalization as a Risk Factor for Recurrence of Clostridioides difficile Infection: Systematic Review and Meta-analysis
39. Burkitt lymphoma presenting with fever of unknown origin and isolated hypoglossal nerve palsy
40. The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation
41. Acid Suppression Medications During Hospitalization as a Risk Factor for Recurrence of Clostridioides difficile Infection: Systematic Review and Meta-analysis.
42. Lyme Disease: Public Education Key to Appropriate Care
43. How Do You Measure Up: Quality Measurement for Improving Patient Care and Establishing the Value of Infectious Diseases Specialists
44. Histoplasmosis Endophthalmitis – Case Report and Review
45. Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection
46. Infective Endocarditis in Intravenous Drug Users: A Comparison of Human Immunodeficiency Virus Type 1-Negative and -Positive Patients
47. Advertising and Indications for Drug Use [with Reply]
48. Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials
49. Successful Treatment of Bacteremia in the Post-Acute Setting – Another Opportunity to Limit Readmission
50. How Do You Measure Up: Quality Measurement for Improving Patient Care and Establishing the Value of Infectious Diseases Specialists.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.